Numerous c-mesenchymal-epithelial transition(c-MET)inhibitors have been reported as potential anticancer agents.However,most fail to enter clinical trials owing to poor efficacy or drug resistance.To date,the scaffold...Numerous c-mesenchymal-epithelial transition(c-MET)inhibitors have been reported as potential anticancer agents.However,most fail to enter clinical trials owing to poor efficacy or drug resistance.To date,the scaffold-based chemical space of small-molecule c-MET inhibitors has not been analyzed.In this study,we constructed the largest c-MET dataset,which included 2,278 molecules with different struc-tures,by inhibiting the half maximal inhibitory concentration(IC_(50))of kinase activity.No significant differences in drug-like properties were observed between active molecules(1,228)and inactive mol-ecules(1,050),including chemical space coverage,physicochemical properties,and absorption,distri-bution,metabolism,excretion,and toxicity(ADMET)profiles.The higher chemical diversity of the active molecules was downscaled using t-distributed stochastic neighbor embedding(t-SNE)high-dimensional data.Further clustering and chemical space networks(CSNs)analyses revealed commonly used scaffolds for c-MET inhibitors,such as M5,M7,and M8.Activity cliffs and structural alerts were used to reveal“dead ends”and“safe bets”for c-MET,as well as dominant structural fragments consisting of pyr-idazinones,triazoles,and pyrazines.Finally,the decision tree model precisely indicated the key structural features required to constitute active c-MET inhibitor molecules,including at least three aromatic het-erocycles,five aromatic nitrogen atoms,and eight nitrogeneoxygen atoms.Overall,our analyses revealed potential structure-activity relationship(SAR)patterns for c-MET inhibitors,which can inform the screening of new compounds and guide future optimization efforts.展开更多
目的:探讨肝细胞生长因子(H G F)及其受体(C-M et)与子宫内膜异位症发病机制的关系。方法:采用链霉素抗生物素蛋白-过氧化物酶(S-P)法检测45例(增生期20例,分泌期25例)盆腔子宫内膜异位症及30例(增生期12例,分泌期18例非子宫内膜异位症...目的:探讨肝细胞生长因子(H G F)及其受体(C-M et)与子宫内膜异位症发病机制的关系。方法:采用链霉素抗生物素蛋白-过氧化物酶(S-P)法检测45例(增生期20例,分泌期25例)盆腔子宫内膜异位症及30例(增生期12例,分泌期18例非子宫内膜异位症妇女的在位子宫内膜的H G F与C-M et的免疫表达水平。结果:(1)盆腔子)宫内膜异位症的在位子宫内膜的H G F、C-M et表达水平显著增高P=0.006,P=0.001)。(2)H G F与C-M et呈正相(关(异位症及对照组r均为0.945)。(3)H G F与C-M et均随月经发生周期性变化(分泌期高于增生期,对照组H G F、C-M et分别为P=0.015、P=0.023;内异症组H G F、C-M et分别为P=0.003、P=0.015)。结论:类似肿瘤转移和浸润机制,H G F/C-M et系统可能参与了子宫内膜异位症的发病。展开更多
基金supported by the National Natural Science Foundation of China(Grant Nos.:82173699 and 32200531)Shanghai Jiao Tong University Trans-Med Awards Research,China(STAR Project No.:20230101)Shanghai Science and Technol-ogy Commission,China(Grant No.:23DZ2290600).
文摘Numerous c-mesenchymal-epithelial transition(c-MET)inhibitors have been reported as potential anticancer agents.However,most fail to enter clinical trials owing to poor efficacy or drug resistance.To date,the scaffold-based chemical space of small-molecule c-MET inhibitors has not been analyzed.In this study,we constructed the largest c-MET dataset,which included 2,278 molecules with different struc-tures,by inhibiting the half maximal inhibitory concentration(IC_(50))of kinase activity.No significant differences in drug-like properties were observed between active molecules(1,228)and inactive mol-ecules(1,050),including chemical space coverage,physicochemical properties,and absorption,distri-bution,metabolism,excretion,and toxicity(ADMET)profiles.The higher chemical diversity of the active molecules was downscaled using t-distributed stochastic neighbor embedding(t-SNE)high-dimensional data.Further clustering and chemical space networks(CSNs)analyses revealed commonly used scaffolds for c-MET inhibitors,such as M5,M7,and M8.Activity cliffs and structural alerts were used to reveal“dead ends”and“safe bets”for c-MET,as well as dominant structural fragments consisting of pyr-idazinones,triazoles,and pyrazines.Finally,the decision tree model precisely indicated the key structural features required to constitute active c-MET inhibitor molecules,including at least three aromatic het-erocycles,five aromatic nitrogen atoms,and eight nitrogeneoxygen atoms.Overall,our analyses revealed potential structure-activity relationship(SAR)patterns for c-MET inhibitors,which can inform the screening of new compounds and guide future optimization efforts.
基金supported by the National Natural Science Foundation of China(No.81472656)Anhui Provincial Natural Science Foundation(No.2022AH040224)+2 种基金Anhui Provincial Natural Science Foundation(No.2023AH051991)Key Research Project at the School Level of Bengbu Medical College(No.Byycx23084)Bengbu Medical College National College Students'Innovation and Entrepreneurship Training Program Project(No.202310367011).
文摘目的:探讨肝细胞生长因子(H G F)及其受体(C-M et)与子宫内膜异位症发病机制的关系。方法:采用链霉素抗生物素蛋白-过氧化物酶(S-P)法检测45例(增生期20例,分泌期25例)盆腔子宫内膜异位症及30例(增生期12例,分泌期18例非子宫内膜异位症妇女的在位子宫内膜的H G F与C-M et的免疫表达水平。结果:(1)盆腔子)宫内膜异位症的在位子宫内膜的H G F、C-M et表达水平显著增高P=0.006,P=0.001)。(2)H G F与C-M et呈正相(关(异位症及对照组r均为0.945)。(3)H G F与C-M et均随月经发生周期性变化(分泌期高于增生期,对照组H G F、C-M et分别为P=0.015、P=0.023;内异症组H G F、C-M et分别为P=0.003、P=0.015)。结论:类似肿瘤转移和浸润机制,H G F/C-M et系统可能参与了子宫内膜异位症的发病。
